Funding profile · Quick commerce pharmacy

Farmako Healthcare

A Gurugram medicine delivery startup with about 1.6 million dollars in press-reported funding and no SEC or MCA capital filing that confirms it. Here is what the public record shows, and where the numbers disagree.

$1.6MReported raise, Aug 2024, company and press stated
$1.5MSeed funding reported by Forbes, as of May 2022
Rs13.5CrFY25 revenue reported by Inc42, about $1.6M, up 26.5% year over year
Rs10KPaid up capital on the MCA record, against Rs1 lac authorized

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2020 Y Combinator, Summer 2020 batch $150,000 reported by founder Y Combinator Interview
By May 2022 Seed $1.5M reported Backend Capital, HOF Capital, Soma Capital, Y Combinator Forbes profile
Aug 2024 Seed, reported as expansion capital $1.6M reported 535 West Capital, Bayhouse Capital, Goodwater Capital, Unpopular Ventures, Jude Gomila, existing investors Press reports
Jun 2025 Seed, per Tracxn Not disclosed publicly 1 investor, per Tracxn Aggregator, amount withheld
Since Aug 2024 Series A, reported as in talks Target not disclosed None named Company-stated

What the filings show

No SEC Form D was found for Farmako Healthcare, for a US entity named Farmako, Inc., or for any related vehicle, in the records assembled for this review or through a direct check of EDGAR. Company data aggregator Tracxn separately lists a Farmako, Inc. legal entity in the United States, incorporated on May 27, 2020, with two employees as of a March 2020 snapshot, a date that predates the entity’s own incorporation and appears to be a data error on the aggregator’s part rather than a confirmed fact. No filing activity for that entity was located.

The closest thing to a capital filing on record is the Ministry of Corporate Affairs registration for Farmako Healthcare Private Limited, CIN U85100UP2019PTC120231. As of the record checked, the company’s authorized share capital is Rs1 lac and its paid up capital is Rs10,000, both nominal figures that reflect the entity’s initial registration rather than any later funding round. Indian private companies commonly keep paid up capital low while raising money through preference shares or premium, so this gap between the MCA record and the 1.5 to 1.6 million dollar rounds reported in the press is not by itself evidence of anything irregular, only a reminder that the MCA snapshot available here does not capture the funding history on its own.

Reading the numbers

  1. Two rounds, two very similar totals.Forbes reported 1.5 million dollars in seed funding as of May 2022, naming Backend Capital, HOF Capital, Soma Capital and Y Combinator. Press coverage in August 2024 reported a further 1.6 million dollars from a different set of names, 535 West Capital, Bayhouse Capital, Goodwater Capital, Unpopular Ventures and Jude Gomila, plus unnamed existing investors. Neither report discloses a post money valuation or share price, so it is not possible to tell from public sources whether the 2024 round priced the company higher than in 2022.
  2. Aggregators do not agree on the running total.Inc42 lists total funding just over 1.6 million dollars across three rounds. Tracxn lists 3.1 million dollars across three rounds, including a June 2025 round whose amount it withholds behind a paywall. Since neither aggregator publishes its underlying filings for Farmako, the gap between 1.6 million and 3.1 million dollars in total funding cannot be resolved from the sources checked here.
  3. The Series A has not visibly closed.Founders told YourStory in August 2024 that they were in talks to close a Series A round later that year. Inc42’s company profile still listed Farmako at Pre-Series A stage as of its most recent update. No press release or Form D announcing a closed Series A was found.
  4. Revenue is growing faster than the disclosed funding would suggest is easy.Inc42 reports FY25 revenue of Rs13.5 crore, about 1.6 million dollars, up 26.5 percent from Rs10.7 crore in FY24. That growth rate, if the underlying statutory filings are accurate, is a more concrete data point than the funding totals, since it should trace back to filed financial statements rather than a press quote.
  5. The MCA capital structure has not been updated to reflect any of this.The authorized and paid up capital figures on record are small enough that they predate any of the reported funding rounds, which typically shows up in later filings, share allotment returns or in an increased authorized capital that was not visible in the record accessed for this page.

Commercial signals

Signal Detail Source type
Order volume More than 16,000 deliveries a month and annual gross order value above 1 million dollars, as of August 2024. Company-stated
Revenue Rs13.5 crore in FY25, up 26.5% from Rs10.7 crore in FY24, per Inc42’s reading of filed financials. Independent reporting
Employee count Reported at 40 in 2020 by Y Combinator, 62 to 63 as of 2025 by Inc42 and Tracxn. Aggregator
Recognition Aman Bhandula named to the Forbes 30 Under 30 Asia, Healthcare and Science, 2022 list. Independent record
Government partnership Official partner of the Ayushman Bharat Digital Mission’s ABHA Health ID program since 2022, company says. Company-stated

What to watch

  • A Form D or other SEC filing for Farmako, Inc., the US entity named in aggregator data, which has not yet appeared.
  • Confirmation of whether the Series A discussed in 2024 has closed, and at what size.
  • An updated MCA filing showing paid up capital or authorized capital that matches the funding reported in the press.
  • A reconciliation of the gap between Inc42’s and Tracxn’s total funding figures for the company.

The Farmako Healthcare story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Reframe: Shared investor: Goodwater. A subscription app from Atlanta that helps people cut back on or quit drinking, built on habit change rather than treatment
  • Fitia: Shared investor: Goodwater. A Lima-built AI meal planner and calorie counter that says it has passed 10 million users across the Spanish-speaking world and is now pushing into the United States
  • Zealth: Shared investor: Goodwater. A Singapore and Mumbai company that built CareShare, software for watching cancer patients between hospital visits
  • Bemlo: Shared investor: Goodwater. A Stockholm platform that started as a marketplace matching nurses and doctors with short term shifts, then bought a competitor to become an AI scheduling tool for

Sources

  1. Public recordFarmako Healthcare Private Limited, company record, CIN U85100UP2019PTC120231Tofler, updated Aug 15, 2026
  2. Public recordFarmako legal entities and funding summaryTracxn, accessed Sep 25, 2026
  3. Independent reportingFarmako company profile, funding stage and FY25 revenueInc42 Datalabs, accessed Sep 25, 2026
  4. IndependentY Combinator-backed healthtech startup Farmako raises $1.6M for expansionYourStory, Trisha Medhi, Aug 12, 2024
  5. Independent recordFarmako profile, Forbes 30 Under 30 Asia, Healthcare and Science 2022Forbes, accessed Sep 25, 2026
  6. IndependentFarmako Raises USD 1.6M in FundingFinSMEs, Aug 14, 2024
  7. IndependentFarmako Bags $1.6 Mn Investment for Medicine Delivery Service in DelhiDigital Health News, Jayati Dubey, Aug 13, 2024
  8. CompanyFarmako Healthcare company pageY Combinator, accessed Sep 25, 2026

Compiled from Indian corporate registry data, aggregator profiles and published reports as of September 25, 2026. No SEC Form D was located for Farmako Healthcare or a related US entity as of this review. Healthcare Venture Capital Fund holds no position in Farmako. This page is not an offer to sell or a recommendation to buy any security.